The aim of this investigation is to assess the benefit of screening for vitamin B12 deficiency and other target diseases (homocystinuria [HU], propionic acidaemia [PA] and methylmalonic aciduria [MMA]) in extended newborn screening (ENS). Newborn screening for the 4 target diseases is compared with no screening. The focus of the assessment is on patient-relevant outcomes.
